Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of rMenB+OMV NZ Vaccine in Korean Adolescents
KCT0001103Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Multicomponent meningococcal B vaccine in meningococcal disease, sponsored by Novartis. Primary endpoints: Immunogenicity against Neisseria meningitidis serogroup B and Safety and tolerability of rMenB+OMV NZ. Started Nov 2013; status: completed.
02
Drugs
Multicomponent meningococcal B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on KCT0001103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001103.